The University of Colorado Denver | Anschutz Medical Campus (CU Denver/Anschutz) is dedicated to ensuring a safe and secure environment for our faculty, staff, students, and visitors. To assist in achieving that goal, we conduct background investigations for all prospective employees.
CU Denver/Anschutz is committed to recruiting and supporting a diverse student body, faculty and administrative staff. The university strives to promote a culture of inclusiveness, respect, communication and understanding. We encourage applications from women, ethnic minorities, persons with disabilities and all veterans. The University of Colorado is committed to diversity and equality in education and employment.
The Immigration Reform and Control Act requires that verification of employment eligibility be documented for all new employees by the end of the third day of work. Alternative formats of this ad are available upon request for persons with disabilities.
|apply||posted on||investigator||laboratory focus||position description||contact|
|04/20/2022||Jean M. Mulcahy Levy||Our lab focuses on brain tumor biology and the development of new therapies for pediatric brain tumors.||We are looking for someone with cancer biology experience, epigenetic experience and the ability to work independently.||Jean.MulcahyLevy@cuanschutz.edu|
|04/13/2022||Cecilia Caino||The Caino lab studies the impact of organelle dynamics, key signaling pathways activated in metastatic cancer, and cancer metabolism in cancer progression. Visit external link for more information.||The Caino lab in the Department of Pharmacology has an opening for a full-time Postdoctoral Fellow to join our team Available projects include studies on the role of mitochondria shape, number and subcellular distribution in tumor cell invasion and metastatic dissemination (see Caino et al, PNAS 2015 Jul 14;112(28):8638-43; Caino et al, Nat Commun. 2016 Dec 19;7:13730). Alternatively, the postdoctoral fellow may work on understanding the role of the Intergrated Stress response (ISR) as a sensor of mitochondrial homeostasis and target for metastatic disease. See recent publications from our lab: Furnish et al, Mol Cancer Res. 2022 Jan 6. doi: 10.1158/1541-7786;Ghosh et al, PNAS. 2022 Feb 22;119(8):e2115624119). Research will involve biochemistry, molecular biology and cellular biology experimental procedures, high-throughput loss-of-function screenings and work with animal models of cancer and metastatic firstname.lastname@example.org|
|04/11/2022||Diana M. Cittelly||The Cittelly lab aims to unveil the mechanisms that allow cancer cells to spread to and colonize the brain, and to discover novel therapeutic strategies for brain metastasis.||A postdoctoral position available for self-driven and curious candidates with a fresh PhD in Biomedical sciences, Biochemistry, Molecular/ cell Biology, Cancer Biology or Neuroscience to drive a fully funded project aimed to define mechanisms for progression of ER+ brain metastasis in the aging brain. This position will provide a unique opportunity to be part of an enthusiastic research team working towards increasing survival for brain metastasis patients both through basic and translational research. Experience with mammalian tissue culture (i.e, proliferation assays, transfections, etc), transcript level assays (e.g., RT-qPCR, etc.), protein level assays (e.g., western blot, ELISA, etc.), is required. Experience with high-throughput assays (e.g., flow cytometry, CyTOF, RNAseq etc.) and/or multiparametric imaging analysis (nanostring, Vectra Polaris) is desirable, but not necessary. Ability/desire to generate hypotheses, design experiments and troubleshoot errors is a email@example.com|
|04/05/2022||Katja Kiseljak-Vassiliades, DO and Margaret E. Wierman, MD||Our research is focused on underlying mechanism and development of new therapeutics for adrenocortical carcinoma (ACC). ACC is an orphan malignancy with five-year survival less than 35%. No targeted therapies have been successful to date.||A position for a full-time post-doctoral fellow to investigate the mechanism underlying adrenocortical carcinogenesis with focus on developmental therapeutics. In vitro approaches include mammalian cell culture, molecular biology, microscopy, immunohistochemistry, functional genomics, proteomics, high throughput drug screening, and genome-wide sequencing. In vivo approaches include patient derived xenograft mouse models, xenograft models, humanized mouse models and subcutaneous mouse models. Ability to design and implement new protocols. Ability to carry out established protocols of the laboratory. The candidate should have background in cellular and molecular biology as well as translational biology. Competency with experimental design, quantitative analysis, literature review, critical thinking, and the ability to present in small group settings are required. The candidate must be a highly motivated and resourceful firstname.lastname@example.org (cell:240-606-6632)|
|03/14/2022||Ross Kedl||Our primary focus is defining what drives strong CD8 T cell responses to vaccines||Some current projects with potential space for a new postdoc include: determining the unique metabolic state vaccine-elicited T cells (Tvac) adopt and how this might be exploited to enhance prophylactic or therapeutic (cancer) vaccine strategies; clarifying the transcription factor networks driving the development of memory Tvac and infection-elicited T cells (Tinf); a nearly completely dry-lab data analysis project comparing the transcriptomes of Tvac and Tinf during their priming, peak effector, and memory stages; and, defining the role(s) for B cells in promoting T cell responses to email@example.com|
|02/22/2022||Daniel Matlock, MD, MPH, Larry Allen, MD MHS, Laura Scherer, PhD||The position sits within the Colorado Program for Patient Centered Decisions (CPPCD) as part of the Adult & Child Consortium for Health Outcomes Research & Delivery Science (ACCORDS).||The CPPCD is led by a multidisciplinary team of established researchers focused on shared decision making and patient centered care. Researchers at CPPCD conduct studies to promote informed medical decisions, e.g. about cancer screening, the implementation of cardiac devices, end of life care and hospice. Our research examines the psychological aspects of health decision making, including risk communication and the influence of emotions and motivations on patients’ medical decisions. The fellowship in CPPCD provides advanced training to health services researchers and clinicians and prepares fellows for positions in academic medicine. The CPPCD postdoctoral fellow collaborates on established projects and is encouraged to conduct independent research with an emphasis on manuscript writing and grant submission. Preference will be given to a candidate with a strong interest in heart failure and health decision making.||Dan Matlock, MD, MPH firstname.lastname@example.org|
|01/18/2022||Dr. Minghua Tang||We are interested in the early dietary impact on infant development, including growth, gut microbiota, immunity, sleep behaviors and neurodevelopment. Keywords: Nutrition, Gut Microbiota, Clinical Research, Obesity Prevention, Pediatrics||This postdoctoral fellow will work primarily on an NIH-funded clinical trial investigating early dietary intakes on infant growth, risk of overweight and gut microbiota development. Responsibilities include coordinating the clinical trial, working with and supervising research assistants, conducting study visits, collecting and analyzing data, and writing pilot and training grants and manuscripts. The postdoctoral fellow is also expected to attend and present at Nutrition Seminars, journal clubs, career development training sessions and national conferences. The trainee is strongly encouraged to apply for the Nutrition T32 fellowship and/or the NIH F32 fellowship in year 2 or 3.||Contact: Minghua.Tang@CUAnschutz.edu Office: 303-724-3248|
|12/07/2021||Katie Rennie, Ph.D.||We study how the vestibular system of the inner ear mediates the sense of balance||An NIH R01-funded post-doctoral position is available in the department of Otolaryngology, Head & Neck Surgery in the Rennie lab at the University of Colorado School of Medicine in Aurora, Colorado. Currently there is little known about mechanisms underlying vestibular dysfunction during aging. Experiments will investigate the properties of vestibular hair cells and associated afferent neurons in aging rodents. This position will be based primarily in Dr. Katie Rennie’s lab as part of a collaborative effort with Dr. Anthony Peng’s lab. Minimum qualifications for candidates include a MD or Ph.D. in Neuroscience, Neurophysiology, Cell Biology, Bioengineering or a similar field. Experience in patch clamp electrophysiology, rodent handling, inner ear biology, immunohistochemistry and/or surface electrode recordings are preferred, but not essential. Ideal candidates are highly motivated and articulate team email@example.com (303 724 3070); firstname.lastname@example.org|
|09/22/2021||Raphael Nemenoff, PhD||The Nemenoff laboratory is focused on examining molecular pathways that regulate the progression and metastasis of lung cancer.||This position reports directly to Dr. Raphael Nemenoff in the Division of Renal Diseases and Hypertension and is responsible for designing and conducting experiments to explore the role of the tumor microenvironment in mediating therapeutic response in preclinical models of non-small cell lung cancer(NSCLC). The project uses an orthotopic immunocompetent model of lung cancer to study mechanisms associated with response to both immunotherapy and targeted therapy. Our group has developed a panel of murine models and murine lung cancer cells comprising the major oncogenic drivers of human NSCLC. Proposed studies focus on the defining critical interactions that determine the depth and duration of response to specific therapeutic approaches.||Betsy Pike, Renal Division Human Resources, email@example.com|
|05/28/2021||Mary Weiser-Evans, PhD, FAHA||The Weiser-Evans laboratory uses fate-mapping genetic approaches combined with molecular analyses such as spatial transcriptomics, RNA-Seq, ChIP, and CyTOF mass cytometry to define mechanisms regulating cardiovascular disease progression.||In vivo mouse genetic approaches are complemented by in vitro studies. Human tissues are used to validate findings from pre-clinical studies in order to define the translational significance of our findings. Select projects include defining the role of PTEN promoter hypermethylation as a key regulator of cardiovascular disease progression as well as defining the mechanisms driving smooth muscle-to-stem cell reprogramming, determining the distinct functions of SMC-derived stem cells in the maintenance and repair of the vessel wall as well as their role in disease progression. Applicants should be highly motivated, detail-oriented, with excellent communication, writing, and organizational skills. Applicants must hold a Ph.D. or an equivalent degree in life sciences.||Betsy Pike, Renal Division Human Resources, firstname.lastname@example.org|